Prakash Kulkarni

List of Publications by Year
in descending order

52 papers	1,516 citations	567281 15 h-index	345221 36 g-index
52 all docs	52 docs citations	52 times ranked	2387 citing authors

#	Article	IF	Citations
1	Intrinsic disorder, extraterrestrial peptides, and prebiotic life on the earth. Journal of Biomolecular Structure and Dynamics, 2023, 41, 5481-5485.	3.5	2
2	Co-opting disorder into order: Intrinsically disordered proteins and the early evolution of complex multicellularity. International Journal of Biological Macromolecules, 2022, 201, 29-36.	7.5	7
3	Intrinsically Disordered Proteins: Critical Components of the Wetware. Chemical Reviews, 2022, 122, 6614-6633.	47.7	48
4	Cancer: More than a geneticistâ€™s Pandoraâ€™s box. Journal of Biosciences, 2022, 47, .	1.1	2
5	Dynamic Phenotypic Switching and Group Behavior Help Non-Small Cell Lung Cancer Cells Evade Chemotherapy. Biomolecules, 2022, 12, 8.	4.0	13
6	Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. Journal of Clinical Medicine, 2021, 10, 188.	2.4	14
7	Coupled Feedback Loops Involving PAGE4, EMT and Notch Signaling Can Give Rise to Non-Genetic Heterogeneity in Prostate Cancer Cells. Entropy, 2021, 23, 288.	2.2	6
8	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. Future Science OA, 2021, 7, FSO662.	1.9	1
9	Quantifying Cancer: More Than Just a Numbers Game. Trends in Cancer, 2021, 7, 267-269.	7.4	4
10	Exploring Energy Landscapes of Intrinsically Disordered Proteins: Insights into Functional Mechanisms. Journal of Chemical Theory and Computation, 2021, 17, 3178-3187.	5.3	21
11	Group Behavior and Emergence of Cancer Drug Resistance. Trends in Cancer, 2021, 7, 323-334.	7.4	21
12	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. Cancers, 2021, 13, 2653.	3.7	2
13	Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). British Journal of Cancer, 2021, 125, 582-592.	6.4	4
14	The Boscombe Valley mystery: A lesson in the perils of dogmatism in science. Journal of Biosciences, 2021, 46, 1.	1.1	1
15	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2021, 20, 1820-1835.	4.1	9
16	Intrinsically disordered proteins: Chronology of a discovery. Biophysical Chemistry, 2021, 279, 106694.	2.8	18
17	Protein conformational dynamics and phenotypic switching. Biophysical Reviews, 2021, 13, 1127-1138.	3.2	9
18	The Boscombe Valley mystery: A lesson in the perils of dogmatism in science. Journal of Biosciences, 2021, 46, .	1.1	0

#	Article	IF	Citations
19	The Mitochondrion as an Emerging Therapeutic Target in Cancer. Trends in Molecular Medicine, 2020, 26, 119-134.	6.7	121
20	Presence and structureâ€activity relationship of intrinsically disordered regions across mucins. FASEB Journal, 2020, 34, 1939-1957.	0.5	7
21	Integrating Clinical and Translational Research Networksâ€"Building Team Medicine. Journal of Clinical Medicine, 2020, 9, 2975.	2.4	5
22	Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. IScience, 2020, 23, 101692.	4.1	9
23	A Non-genetic Mechanism Involving the Integrin Î²4/Paxillin Axis Contributes to Chemoresistance in Lung Cancer. IScience, 2020, 23, 101496.	4.1	27
24	Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research. Journal of Clinical Medicine, 2020, 9, 2433.	2.4	9
25	Intrinsically Disordered Proteins: Insights from PoincarÃ©, Waddington, and Lamarck. Biomolecules, 2020, 10, 1490.	4.0	8
26	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. Journal of Clinical Medicine, 2020, 9, 1870.	2.4	16
27	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. Lung Cancer, 2020, 146, 174-181.	2.0	8
28	Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell, 2020, 38, 79-96.e11.	16.8	389
29	FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials. Expert Opinion on Investigational Drugs, 2020, 29, 399-409.	4.1	59
30	Implementing Lung Cancer Screening and Prevention in Academic Centers, Affiliated Network Offices and Collaborating Care Sites. Journal of Clinical Medicine, 2020, 9, 1820.	2.4	7
31	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Settingâ€"Role of Academic and Hybrid Modeling. Journal of Clinical Medicine, 2020, 9, 1884.	2.4	5
32	Characterization of RNAâ€binding motif 3 (RBM3) protein levels and nuclear architecture changes in aggressive and recurrent prostate cancer. Cancer Reports, 2020, 3, e1237.	1.4	4
33	Stromalâ€epithelial interactions in prostate cancer: Overexpression of PAGE4 in stromal cells inhibits the invasive ability of epithelial cells. Journal of Cellular Biochemistry, 2020, 121, 4406-4418.	2.6	7
34	Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. International Journal of Oncology, 2020, 57, 80-86.	3.3	1
35	Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. Journal of Clinical Medicine, 2019, 8, 1038.	2.4	8
36	Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. Journal of Clinical Medicine, 2019, 8, 1723.	2.4	5

#	Article	IF	Citations
37	Phenotypic Switching of NaÃ¯ve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. Journal of Clinical Medicine, 2019, 8, 1726.	2.4	26
38	EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. Oncogenesis, 2019, 8, 49.	4.9	17
39	Intrinsically Disordered Proteins in Chronic Diseases. Biomolecules, 2019, 9, 147.	4.0	52
40	Intrinsically disordered proteins and phenotypic switching: Implications in cancer. Progress in Molecular Biology and Translational Science, 2019, 166, 63-84.	1.7	15
41	Structural and Dynamical Order of a Disordered Protein: Molecular Insights into Conformational Switching of PAGE4 at the Systems Level. Biomolecules, 2019, 9, 77.	4.0	19
42	Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. Molecular Therapy - Oncolytics, 2019, 13, 1-6.	4.4	26
43	EphB4: A promising target for upper aerodigestive malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2018, 1869, 128-137.	7.4	16
44	The Genetic/Non-genetic Duality of Drug â€˜Resistanceâ€™ in Cancer. Trends in Cancer, 2018, 4, 110-118.	7.4	201
45	Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biology and Therapy, 2018, 19, 316-327.	3.4	86
46	Intrinsically Disordered Proteins and the Janus Challenge. Biomolecules, 2018, 8, 179.	4.0	7
47	Single Molecule FRET: A Powerful Tool to Study Intrinsically Disordered Proteins. Biomolecules, 2018, 8, 140.	4.0	50
48	Prostate-Associated Gene 4 (PAGE4): Leveraging the Conformational Dynamics of a Dancing Protein Cloud as a Therapeutic Target. Journal of Clinical Medicine, 2018, 7, 156.	2.4	10
49	Inhibiting crosstalk between MET signaling and mitochondrial dynamics and morphology: a novel therapeutic approach for lung cancer and mesothelioma. Cancer Biology and Therapy, 2018, 19, 1023-1032.	3.4	12
50	Intrinsically Disordered Proteins: The Dark Horse of the Dark Proteome. Proteomics, 2018, 18, e1800061.	2.2	66
51	PAGE4 and Conformational Switching: Insights from Molecular Dynamics Simulations and Implications for Prostate Cancer. Journal of Molecular Biology, 2018, 430, 2422-2438.	4.2	36
52	Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Nonâ€small Cell Lung Cancer and Malignant Mesothelioma. FASEB Journal, 2018, 32, 835.9.	0.5	0